Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
How Should Medical Affairs Engage on Social Media
Summary
In this episode, Tom Caravela and Sarah Snyder delve into the vital role of social media for Medical Science Liaisons (MSLs). They discuss its evolution in medical affairs, platforms for professionals, and the benefits of social engagement for relationship building. Sarah offers insights on balancing personal and professional brands, best practices for engaging with healthcare professionals, and staying updated on medical advancements. They also cover social media pitfalls, thought leadership, compliance considerations, and future trends in digital tools and AI's impact on MSL roles, concluding with a look at evolving digital opinion leaders.
Key Points
- Understanding and engaging with HCPs and KOLs on social media is essential for MSLs in today's digital world, as it helps speed up relationship building and keeps them informed about current trends and discussions in their field.
- MSLs should focus on social listening and following key hashtags, especially during conferences, to stay updated on the latest scientific advancements and to see where their KOLs are active without necessarily having to post or comment themselves.
- It's crucial for MSLs to maintain a clear separation between their personal and professional social media accounts, adhere strictly to their company's compliance guidelines, and avoid engaging in debates or commenting on product-specific information to mitigate risks.
Medical Science Liaisons, social media engagement, healthcare professionals, digital opinion leaders, compliance in medical affairs
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
iNIZIO